There are currently 191 clinical trials in Torrance, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Harbor UCLA Medical Center, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance Memorial Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
POLARx Post Approval Study (POLARx PAS)
NCT06170606
Recruiting
To collect clinical data on safety, effectiveness and procedural success of Boston Scientific's Cardiac Cryoablation System (includes all BSC commercially available POLARx/POLARx Fit catheters) when used to perform pulmonary vein isolation (PVI) in the ablation treatment of de novo Atrial Fibrillation (AF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Torrance Memorial Medical Center, Torrance, California
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
NCT05719441
Recruiting
A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in addition to ART during acute HIV infection (AHI) will be safe. * Participants who receive combination bNAb therapy in addition to ART during AHI will be more likely to demonstrate a delay in time to HI... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: 603, Harbor University of California Los Angeles Center CRS, Torrance, California
Conditions: Acute HIV Infection
Register for Updates
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)
NCT06510816
Recruiting
The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/24/2025
Locations: Macula Retina Vitreous Research Institute, Torrance, California
Conditions: Geographic Atrophy
Register for Updates
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
NCT04763200
Recruiting
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/24/2025
Locations: Torrance Memorial Medical Center, Torrance, California
Conditions: Left Ventricular Dysfunction, Coronary Artery Disease
Register for Updates
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482
Recruiting
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/24/2025
Locations: Harbor University of California at Los Angeles Medical Center, Torrance, California
Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Register for Updates
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902
Recruiting
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: City of Hope South Bay, Torrance, California
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879
Recruiting
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: The Lundquist Institute ( Site 3423), Torrance, California
Conditions: Essential Thrombocythemia
Register for Updates
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
NCT04796337
Recruiting
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Harbor UCLA Medical Center ( Site 1028), Torrance, California
Conditions: PAH, Pulmonary Arterial Hypertension
Register for Updates
Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
NCT04502316
Recruiting
The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.
Gender:
ALL
Ages:
All
Trial Updated:
03/21/2025
Locations: COR Healthcare Medical Associates, Torrance, California
Conditions: Heart Failure
Register for Updates
RECOVER-ENERGIZE Platform Protocol
NCT06404047
Recruiting
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California
Conditions: Long COVID, Long Covid19, Long Covid-19
Register for Updates
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
NCT06096779
Recruiting
The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Harbor UCLA Medical Center, Torrance, California
Conditions: Hepatocellular Carcinoma
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
03/20/2025
Locations: CenExel CNS-TO (Collaborative Neuroscience Research), Torrance, California
Conditions: Major Depressive Disorder
Register for Updates